Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab PRO Study in Severe or Refractory Asthma with Chronic Cough
jRCT1030230280Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tezepelumab in asthma and chronic cough, sponsored by AstraZeneca. Primary endpoint: Primary: Mean change in ACQ-6 at week 52 from baseline. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
asthmachronic cough
Beyond the preview
Go deeper on jRCT1030230280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230280.